As a humanized anti-IgE monoclonal antibody, omalizumab was approved for moderate-to-severe asthma first in 2003 by the U.S. Food and Drug Administration (FDA), then in 2005 by the European Medicines Agency (EMA), subsequently in 2018 by National Medical Products Administration (NMPA) in China, and then further approved for severe CRSwNP in 2020 by the FDA.15 This evidence concerns the gene IGHE and chronic rhinosinusitis with nasal polyps.